Malignant Gliomas

19 registered clinical trials studyying Malignant Gliomas.

Status	Trial	Sponsor	Phase
Active Not Recruiting	Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Glioma NCT03212742	Centre Francois Baclesse	Phase 1 / Phase 2
Completed	5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor NCT02632370	Constantinos Hadjipanayis	—
Completed	Fluorescence and Glioma Heterogeneity NCT02155452	Tata Memorial Hospital	—
Completed	Clinical Development of Cancer-Specific MRS Biomarkers in Malignant Gliomas NCT02388659	University of Texas Southwestern Medical Center	—
Completed	Clinical Development of MR Spectroscopy and Imaging in Brain Cancers NCT02731521	University of Texas Southwestern Medical Center	—
Unknown	Efficacy and Safety of TMZ Plus CDDP in the Patients With Recurrent Malignant Gliomas NCT01670890	Peking Union Medical College Hospital	Phase 2
Terminated	Imaging Study of Glioblastomas Treated With Avastin NCT01549392	London Health Sciences Centre	N/A
Completed	Multimodal MR Imaging in Patients With Glioblastoma Treated With Dendritic Cell Therapy NCT01657734	Universitaire Ziekenhuizen KU Leuven	—
Completed	Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Gli NCT00879437	Baylor College of Medicine	Phase 2
Completed	A Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Adults With Malign NCT00704080	Sanofi	Phase 1
Terminated	Sunitinib to Treat Recurrent Brain Cancer NCT00923117	National Cancer Institute (NCI)	Phase 2
Terminated	Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I NCT00671801	M.D. Anderson Cancer Center	Phase 1
Completed	Dose Escalation Study of Vandetanib With Hypofractionated Stereotactic Radiotherapy in Recurrent Malignant Gli NCT00822887	University of Colorado, Denver	Phase 1
Completed	Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas NCT00463073	Rigshospitalet, Denmark	Phase 2
Completed	Clinical and Molecular-Metabolic Phase II Trial of Perifosine for Recurrent/Progressive Malignant Gliomas NCT00590954	Memorial Sloan Kettering Cancer Center	Phase 2
Completed	ZD6474 to Treat Advanced Brain Cancer in Patients NCT00272350	National Cancer Institute (NCI)	Phase 1
Completed	Bevacizumab for Recurrent Malignant Glioma NCT00271609	National Cancer Institute (NCI)	Phase 2
Completed	Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme NCT00165477	Dana-Farber Cancer Institute	Phase 2
Completed	Phase I Trial of CC-8490 for the Treatment of Subjects With Recurrent/Refractory High-Grade Gliomas NCT00074646	Celgene Corporation	Phase 1